Trifarotene Aklief denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for trifarotene aklief are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Issue a "Not FDA-Approved" Denial for Trifarotene (Aklief)

Aklief (trifarotene) received FDA approval in 2019 for the treatment of acne vulgaris. A "not FDA-approved" denial from Aetna is almost certainly an administrative or coding error — either the claim was submitted with a diagnosis code that Aetna's system does not map to trifarotene's approved indication, or Aetna's clinical policy database has not been properly updated. In rare cases, the denial may reflect an off-label use argument if the prescription was written for a patient population or indication outside the FDA-approved labeling.

This is one of the most straightforwardly reversible denial types, because FDA approval is a documented, verifiable fact.

## Why This Denial Is Appealable

A factual error by the insurer — asserting that an FDA-approved drug lacks approval — is a clear ground for appeal. Federal law under the ACA and ERISA requires that coverage decisions be based on accurate clinical and regulatory information. An insurer cannot sustain a "not approved" denial in the face of the FDA label.

## Your Federal Appeal Rights

• Internal appeal: File promptly with the FDA label attached as your primary exhibit. Aetna must respond within the applicable regulatory deadline.
• External review (ACA §2719): If the internal appeal fails, independent external review is available — typically within about four months of the original denial. The IRO's decision is binding on Aetna.
• ERISA §503: Employer-plan members are entitled to a full-and-fair review and all documents used in the denial determination.
• Expedited review: Request expedited review if the delay is causing active harm.

## Documentation to Gather

• FDA label: Download the current prescribing information from DailyMed (dailymed.nlm.nih.gov) confirming trifarotene's FDA-approved status and indication.
• Denial EOB: The exact denial language Aetna used — identify whether they are citing a general "not approved" basis or a specific indication mismatch.
• Prescriber letter: Your dermatologist should confirm the prescription is within the FDA-approved indication, confirm the diagnosis code submitted is correct, and attach the FDA label reference.
• Claim coding review: Ask your pharmacy or prescriber's office to verify that the NDC, diagnosis code, and prescriber NPI were submitted correctly.

## Criteria-Mapping Structure

| Aetna's Denial Basis | Counter-Evidence | Exhibit | |---|---|---| | Drug not FDA-approved | FDA approval confirmed 2019 | DailyMed label printout | | Indication not covered | On-label diagnosis confirmed | Prescriber letter + chart note | | Coding error | Corrected claim codes | Pharmacy / prescriber billing confirmation |

In most cases, this appeal resolves at the internal level once the FDA label is submitted. If it does not, an IRO will almost certainly reverse a denial based on factually incorrect approval status.